Proteasome dysfunction induces excessive proteome instability and loss of mitostasis that can be mitigated by enhancing mitochondrial fusion or autophagy

Eleni N. Tsakiri, Sentiljana Gumeni, Konstantinos Vougas, Diana Pendin, Issidora Papassideri, Andrea Daga, Vassilis Gorgoulis, Gábor Juhász, Luca Scorrano and Ioannis P. Trougakos

Supplemental Information

Supplemental Figures

Figure S1. KD of the *Prosα4* (20S), *Rpn10* (19S) or *Rpt6* (19S) proteasomal genes reduces flies' longevity. Flies' longevity curves after inducible KD of the *Prosα4*, *Rpn10* or *Rpt6* genes. Statistics of the longevity curves are reported in Table S1.

Figure S2. Proteomic analyses by nano-LC-ESI-MS/MS and His2Av stain in larvae tissues after KD of the 20S *Prosβ5* gene. (**A**) Graphical representation of the high resolution iTRAQ proteomics data. Proteins identified by iTRAQ proteomics to be differentially expressed (*vs*. *mCherry* RNAi) after inducible *Prosβ5* RNAi in larval tissues, along with their human orthologs, are reported in Table S2. Data refer to 3rd instar stage larvae not treated with RU486. (**B**) Immunoblot analyses after probing shown tissue lysates with His2Av antibody. (**C**) CLSM visualization of Mito-GFP reporter and of His2Av (immunofluorescence staining) in larvae muscle tissues of the shown genotypes; samples were counterstained with DAPI. White arrow indicates His2Av positive nuclei foci after *Prosβ5* KD; stars denote mitochondrial aggregates, some of which tend to be perinuclear. Gapdh probing (**B**) was used as input reference.

Figure S3. Proteasome KD induces DNA damage. CLSM visualization of propidium iodide and DAPI staining in muscle nuclei of $3rd$ instar stage larvae expressing the shown transgenes.

Figure S4. Disruption of mitochondrial functionality after proteasome KD. (**A**) Immunoblots after BN-PAGE (4% digitonin), for the analysis of mitochondrial RCS assembly, and probing with antibodies against ND-30/NDUFS3 (complex I) and blw/ATP5F1A (complex V); mitochondria were isolated from larvae tissues expressing *mCherry*, *Prosβ5*, *Prosα7* or *Rpn11* RNAi transgenes. (**B**) Mean mitochondrial cristae width in larvae of the shown genotypes. In both cases the Gal4-Tub driver was used. Bars, \pm SD; $n \ge 2$; ***P* < 0.01.

Figure S5. Proteasome dysfunction promotes a cncC-dependent induction of mitostatic genes. Relative expression of *Marf*, *Opa1*, *Drp1*, *ATPsynβ*, *SdhA* and *Lon* genes in 3 rd instar stage control larvae or after KD of the shown proteasomal subunits (larvae were not exposed to RU486). Larvae were also treated with 5 μΜ of the proteasome inhibitor PS-341 in parallel (or not) to *cncC* KD (induced with RU486). Gene expression was plotted *vs*. the respective control set to 1; the *RpL32/rp49* gene expression was used as input reference. Bars, \pm SD; n \geq 2; **P* < 0.05; ***P* < 0.01.

Figure S6. Proteomic analyses by nano-LC-ESI-MS/MS in purified mitochondria after KD of the 20S proteasomal *Prosβ5* subunit; and ref(2)P colocalization with mitochondria in the nervous system and muscle tissues after KD of proteasome subunits. (**A**) Graphical representation of the iTRAQ proteomics data. Proteins identified by iTRAQ proteomics to be differentially expressed (*vs*. *mCherry* RNAi) after inducible *Prosβ5* RNAi in isolated mitochondria from larval tissues, along with their human orthologs, are reported in Table S3. (**B**) Immunoblot analyses of isolated mitochondria of the shown larvae genotypes after probing samples with antibodies against ubiquitin (Ub; left panel) or protein carbonylation (DNP; right panel). (**C**) Graphical representation of the ribosomal 40S RpS27A

and 60S RpL40 proteins domains. (**D**) CLSM visualization of mitochondria (Mito-GFP reporter) in the nervous system of larvae after *Prosβ5* or *Rpn11* KD; tissues were also stained with ref(2)P antibody. (**E**) CLSM visualization of Mito-GFP and ref(2)P distribution in larvae muscle of the shown genotypes; samples were counterstained with DAPI (n, nucleus). (**F, G**) Immunoblot analyses showing ref(2)P expression levels in larvae tissues (**F**) or following mitochondria isolation (**G**). (**H**) Quantitative analysis of mitochondria velocity in larvae nervous tissue after *Prosβ5* KD (see also, Videos S1, S2). White arrows in (**D**, **E**) indicate ref(2)P colocalization with aggregated mitochondria. In (A, B, F, G) data refer to 3rd instar stage larvae not treated with RU486 (driver, Gal4-Tub). blw/ATP5F1A (**B**, **G**) and Actin (**F**) or Gapdh (**G**) probing were used as input reference.

Figure S7. mCherry-Atg8a colocalization with ref(2)P, and blw/ATP5F1A with GFP-Lamp1 in larvae muscles following KD of the *Prosβ5* gene. (**A**) CLSM visualization of mCherry-Atg8a and ref(2)P costaining. (**B**) CLSM visualization of mitochondrial blw/ATP5F1A staining and GFP-Lamp1. White arrows in (**A**), (**B**) indicate sites of colocalization; n, nucleus.

Figure S8. KD of the *Prosβ5* proteasomal gene induces GFP-Lamp1 in larval muscle but results in reduced LysoTracker Red staining; on the contrary, *Rpn11* KD increased LysoTracker Red staining. (**A**) CLSM visualization of GFP-Lamp1 signal and LysoTracker Red staining in control larvae or after KD of the *Prosβ5* gene. (**B**) CLSM visualization of Mito-GFP and LysoTracker Red in control larvae or after KD of the *Prosβ5* or the *Rpn11* genes.

Figure S9. Targeted proteasome KD in the nervous system or muscles promotes systemic effects; ubiquitous proteasome KD in larvae induces metabolic alterations. (**A**, **B**) CLSM visualization of Mito-GFP and ref(2)P localization in larvae nervous system (**A**; shown Figure is an extended view of Fig. S6D, middle panel) and muscles (**B**) after targeted KD of the *Prosβ5* gene in the nervous system [in (**B**) samples were counterstained with DAPI]. Arrows in (**A**) indicate ref(2)P colocalization with aggregated mitochondria, while in (**B**) indicate nerves that express Mito-GFP; dashed arrow in (**B**) denotes ref(2)P staining in Mito-GFP positive nerves and white star ref(2)P staining in underlying muscles. (**C**) Immunoblot analyses, after KD of the *Prosβ5* proteasomal gene in the nervous system (Gal4-D42 driver) or in the muscles (Gal4-Mef2 driver) and probing of isolated brain or muscle samples with antibodies against protein ubiquitination (Ub) or carbonylation (DNP). (**D**) Relative (%) content (*vs*. controls) of GLU, GLY and TREH after *Prosβ5* KD in larvae tissues; data refer to 3rd instar stage larvae not treated with RU486. Gapdh probing (**C**) was used as input reference. In (**D**) control values were set to 100%. Bars, \pm SD; n \geq 2; $*P < 0.05$; $*P < 0.01$.

UAS Prosß5 RNAi, UAS foxo/Mito-GFP, Gal4-Mef2

Figure S10. Higher *cncC* or *foxo* expression levels do not rescue the toxic effects of proteasome loss of function. (**A**) Stereoscope viewing of 3rd instar control (+/Gal4-Tub) or transgenic larvae expressing the indicated transgenes. (**B**) Relative expression of *Rpn11*, *Prosα7*, *Prosβ5*, *Drp1*, *Marf*, *Opa1*, *ATPsynβ*, *Hsc70-3*, *Hsp10*, *Hsp60, Hsp70*, *ref(2)P* and *Atg8α* genes in control samples, after *Prosβ5* KD or after combined *Prosβ5* KD and *cncC* OE. (**C**) Immunoblotting analyses of protein samples from shown transgenic larvae tissues; samples were probed with antibodies Hsp70 and Gapdh. (**D, E**) CLSM visualization of the Mito-GFP reporter in the nervous system (**D**) or in muscle tissues (**E**) of the shown transgenic larvae; samples were stained with a ref(2)P antibody and in (**E**) were also counterstained with DAPI. (**F**) Stereoscope viewing of flies' eyes after targeted eye expression of the indicated transgenes; for control adult flies' eyes (+/Gal4-GMR) see Fig. 4B. Unless otherwise

indicated, data refer to 3rd instar stage larvae not exposed to RU486 (driver, Gal4-Tub). Gene expression was plotted *vs*. the respective control set to 1. Right panels in (**D**) represent increased magnification (white rectangles) from merged CLSM images. White arrows in (**E**) indicate ref(2)P colocalization with aggregated mitochondria. Gapdh (**C**) and *RpL32/rp49* gene (**B**) probing were used as input reference. Bars, \pm SD; $n \ge 2$; $*P < 0.05$; $**P < 0.01$.

Figure S11. Mitochondria visualization in muscle and nervous tissues following KD of the *Prosβ5* gene and *Drp1*^m expression. CLSM visualization of mitochondria (Mito-GFP reporter) in larval muscles (**A**) and nervous (**B**) tissues; dashed lines denote proximal nerves section.

Figure S12. Enhanced *Atg8a* expression alleviates proteasome dysfunction-induced proteome instability. (**A**) Stereoscope viewing of 3rd instar control (+/Gal4-Mef2) or transgenic larvae expressing the shown transgenes in muscles (Gal4-Mef2 driver). (**B**, **C**) Immunoblotting analyses of tissue protein samples from shown transgenic larvae; samples were probed with antibodies against ubiquitinated (Ub) (**B**) and carbonylated (DNP) (**C**) proteins. Gapdh probing was used as input reference.

Figure S13. Our findings indicate that proteasome is a central hub in the wiring of proteostatic, mitostatic, nutrients sensing and likely genome maintenance modules. Therefore, loss of proteasome functionality results in increased genomic instability, as well as in deregulation of proteostatic and mitostatic networks affecting thus all machineries that maintain cellular homeodynamics and energetics.

Supplemental Tables

Table S1. Summary of lifespan experiments.

Table S2. Proteins found to be differentially expressed after inducible *Prosβ5* RNAi (*vs*. *mCherry* RNAi) in larval tissues (nano-LC-ESI-MS/MS proteomics analysis).

Table S3. Proteins found to be differentially expressed after inducible *Prosβ5* RNAi (*vs*. *mCherry* RNAi) in isolated mitochondria from larval tissues (nano-LC-ESI-MS/MS proteomics analysis).

Table S4. Proteins found to be increasingly ubiquitinated in larvae mitochondria after inducible *Prosβ5* RNAi (*vs*. *mCherry* RNAi) (nano-LC-ESI-MS/MS proteomics analysis).

Supplemental Videos

Video S1. Mitochondrial motility in the nervous system (proximal nerves section) of control larvae (~20 s; representative video).

Video S2. Mitochondrial motility in the nervous system (proximal nerves section) after targeted *Prosβ5* RNAi in larvae nervous system (~20 s; representative video).

KEY RESOURCES TABLES

Critical Commercial Assays/Kits

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for reagents may be directed to Ioannis Trougakos (itrougakos@biol.uoa.gr).

Supplemental Materials and Methods

Genes list.

Atg6 (Autophagy-related 6, FBgn0264325, CG5429); *Atg8a* (Autophagy-related 8a, FBgn0052672, CG32672); *ATPsynβ* (ATP synthase, β subunit, FBgn0010217, CG11154); *blw* (bellwether, FBgn0011211, CG3612); *cncC* (cap-n-collar isoform-C, FBgn0262975, CG43286); *Drp1* (Dynamin related protein 1, FBgn0026479, CG3210); *foxo* (forkhead box, sub-group O, FBgn0038197, CG3143); *fzo* (fuzzy onions, FBgn0011596, CG4568); *His2Av* (Histone H2A variant, FBgn0001197, CG5499); *Hsf* (Heat shock factor, FBgn0001222, CG5748); *Hsp23* (Heat shock protein 23, FBgn0001224, CG4463); *Hsp2*6 (Heat shock protein 26, FBgn0001225, CG4183); *Hsp70* (Heatshock-protein-70Bb/a, FBgn0013278/FBgn0013277, CG31359/CG31449); *Keap1* (Keap1, FBgn0038475, CG3962); *Lon* (Lon protease, FBgn0036892, CG8798); *Marf* (Mitochondrial assembly

regulatory factor, FBgn0029870, CG3869); *ND-30* [NADH dehydrogenase (ubiquinone) 30 kDa subunit, FBgn0266582, CG12079)]; *Opa1* (Optic atrophy 1, FBgn0261276, CG8479); *park* (parkin, FBgn0041100, CG10523); *Pink1* (PTEN-induced putative kinase 1, FBgn0029891, CG4523); *Prosα4* (Proteasome α4 subunit, FBgn0004066, CG3422); *Prosα7* (Proteasome α7 subunit, FBgn0023175, CG1519); *Prosβ1* (Proteasome β1 subunit, FBgn0010590, CG8392); *Prosβ2* (Proteasome β2 subunit, FBgn0023174, CG3329); *Prosβ5* (Proteasome β5 subunit, FBgn0029134, CG12323); *ref(2)P* (refractory to sigma P, FBgn0003231, CG10360); *RpL40* (Ribosomal protein L40, FBgn0003941, CG2960); *Rpn6* (Regulatory particle non-ATPase 6, FBgn0028689, CG10149); *Rpn10* (Regulatory particle non-ATPase 10, FBgn0015283, CG7619); *Rpn11* (Regulatory particle non-ATPase 11, FBgn0028694, CG18174); *RpS27A* (Ribosomal protein S27A, FBgn0003942, CG5271); *Rpt6* (Regulatory particle triple-A ATPase 6, FBgn0020369, CG1489); *SdhA* (Succinate dehydrogenase, subunit A (flavoprotein), FBgn0261439, CG17246); *Trxr-1* (Thioredoxin reductase-1, FBgn0020653, CG2151).

Genomic DNA Extraction and PCR analysis.

For checking lines carrying more than one transgene, genomic DNA from flies or larvae was extracted with a Genomic DNA Kit (Thermo Fisher Scientific, K0512). In brief, flies or larvae were homogenized in lysis buffer and the homogenate was incubated for 10 min at 65°C. Chloroform was added and after centrifugation the aqueous phase was collected. DNA was then precipitated with the addition of 1X precipitation buffer. PCR analysis was performed by using the DreamTaq Green PCR Master Mix (Thermo Fisher Scientific, K1082) and PCR products were visualized by agarose gel electrophoresis.

Primers (F: Forward; R: Reverse) sequences were as follows: *Valium 20*-F: ACCAGCAACCAAGTAAATCAAC, *Valium 20*-R: TAATCGTGTGTGATGCCTACC; *cncC*-F: TGGAATTGGGCACCCATGGCG, *cncC*-R: AGTTTGAGTACGTCGTTCAACA; *foxo*-F: CAGTGCCGGATGGAAGAACT, *foxo*-R: ATCCACCAGGATGACTTGCC; *Marf*-F: CCGCTATCCCGGTTCAACTC, *Marf*-R: ACCTTCATGTGATCCCGCTG; *Marf* RNAi-F: CGCGAATTCCCGAGGGCTTTCAGATACGCTACTTC, *SV40*-R: CACAGAAGTAAGGTTCCTTCACAAAGATCC; *Atg8α* -F: ACGCCTTCGAGAAGCGTCGC, *Atg8α*-R: CCAAATCACCGATGCGCGCC; *Opa1*-F: CGAGGAGTTCCTACTTGC, *Opa1*-R: TGAGATTCCGCGAGAACTGG.

Larval brain isolations for immunoblotting.

For larval brain isolation third instar larvae were collected and dissected in PBS into a Petri anatomy dish. Larvae were immobilized with 2 small pins (1 to the top and 1 to the edge of larvae) so that the abdominal region was upwards; cut just above the edge and then a slit was made into the larvae mouth to enable removal of the internal organs and the isolation of the intact brain.

Propidium iodide staining.

For propidium iodide staining fixed larvae tissues were incubated with 400 μg/ml RNAse A (Thermo Fisher Scientific, EN0531) for 40 min in PBS containing 0.3% Triton X-100 (Applichem, A4975), washed 3X with PBS containing 0.3% Triton X-100 and incubated with propidium iodide (500 ng/ml; BioLegend, 421301) for 20 min. Following 3 washes with PBS (Applichem, A9201 PB), samples were mounted in Mowiol® 4-88 (Sigma-Aldrich, 4-88) and viewed in CLSM.

CLSM recording of mitochondria motility in Drosophila Larval Neurons.

To image mitochondria in live segmental nerves, larvae were prepared as described before [1] with minor modifications. Third instar larvae were dissected in Schneider's insect medium (Thermo Fisher Scientific, 21720024). The space between the glass and the coverslip glass was filled with Schneider's insect medium. To track the mitochondria movement, GFP mitochondria were visualized with a Digital Eclipse C1 Nikon CLSM at 25°C. Mitochondria in the proximal segment (A2) and middle segment (A4) of the axons were observed. A 55-μm region of the segmental nerve was photobleached for 15 s with 488 nm light at full intensity from the Digital Eclipse C1 Nikon CLSM (60x objective, zoom factor 4). Immediately after photobleaching, images were collected at a rate of 1 frame/s (zoom factor 2.5) for 280 s. To track and quantify mitochondria movement the NIH ImageJ version 1.62b7 was used with an object tracking macro (MTrackJ) based on software designed by Erik Meijering.

Measurement of GLU, TREH and GLY levels.

GLU, TREH and GLY levels were performed as described previously [2] with minor modifications. Larvae tissues were homogenized in cold PBS for GLU and GLY measurements or with trehalase buffer (5 mM Tris, pH 6.6, 137 mM NaCl, 2.7 mM KCl) for TREH measurement. The clear extract was then incubated for 10 min at 70° C and a small amount was used for protein quantification by Bradford assay. Following centrifugation at max speed for 3 min, 30 µl of diluted (1/4) (or undiluted for TREH measurement) supernatant was transferred to a 96-well plate. The GLU assay was performed by adding in the sample 100 µl of GLU Reagent (Sigma-Aldrich, GAGO-20) and incubating for 30 min at 37ºC. For GLY measurement the same procedure as the GLU assay was followed except that the samples were incubated with or without 1 U of amyloglucosidase (Sigma-Aldrich, A7420). For TREH measurement 100 µl of the GLU Reagent (Sigma-Aldrich, GAGO-20) were added in the samples which were then incubated for 18 hours at 37ºC; followed by incubation (or not) with 0.05 U/ml of trehalase (Sigma-Aldrich, T8778). Absorbance was recorded at 540 nm and the TREH or GLY levels were calculated after the substraction of the GLU measurement at this step from the total amount of free GLU measured after TREH or amyloglucosidase digestion. At least 3 replicates per genotype or experimental condition were performed.

Sample preparation and nano-LC-ESI-MS/MS analysis of iTRAQ labeled peptides.

Larvae tissues or isolated mitochondria were homogenized with the dissolution buffer (0.5 M triethylammonium bicarbonate) from the iTRAQ kit (ABSciex, 4381663), mixed with vortex and after the addition of 0.05% SDS were sonicated (20% power with 0.1-0.2 pulses) for 20 s on ice. Homogenates were centrifuged for 15 min at 13,000 \times g (4 \degree C); supernatant was collected and protein content was measured with the Bradford assay. Recovered protein (50 µg) was diluted in dissolution buffer (solution C) up to a final volume of 20 μl, followed by the addition of 2 μl reducing reagent from the iTRAQ kit; samples were then incubated for 1 h at 60° C. Following the addition of 1 µl cysteine blocking reagent [200 mM methyl methanethiosulfonate (Sigma-Aldrich, 208795) in isopropanol] from the iTRAQ kit, samples were incubated for 10 min at room temperature (RT). Proteins were digested with overnight incubation (at RT in dark) after the addition of 75 ng/µl trypsin (protein:trypsin, 30:1) and were subsequently labeled with the iTRAQ reagents as per manufacturer's instructions.

LC-MS experiments were performed on a Dionex Ultimate 3000 UHPLC system coupled with the high resolution nano-ESI Orbitrap-Elite mass spectrometer (Thermo Fisher Scientific, 168 3rd Avenue. Waltham, MA USA 02451). Individual high-pH RP peptide fractions were reconstituted in 50 μl loading solution composed of 0.1% formic acid. A 5-μl volume was injected and loaded on the Acclaim PepMap 100, 100 μ m \times 2 cm C18, 5 μ m, 100 Å trapping column with the ulPickUp Injection mode; the loading pump was operating at flow rate of 5 μl/min. For the peptide separation, the Acclaim PepMap RSLC, 75 μ m × 50 cm, nanoViper, C18, 2 μ m, 100 Å column retrofitted to a PicoTip emitter was used for multi-step gradient elution. Mobile phase (A) was composed of 0.1% formic acid and mobile phase (B) was composed of 100% acetonitrile, 0.1% formic acid. The peptides were eluted under a 315 minute gradient from 2% (B) to 33% (B). Flow rate was 300 nl/min and column temperature was set at 35°C. Gaseous phase transition of the separated peptides was achieved with positive ion electrospray ionization applying a voltage of 2.5 kV. For every MS survey scan, the top 10 most abundant multiply charged precursor ions between m/z ratio 300 and 2200 and intensity threshold 500 counts were selected with FT mass resolution of 60,000 and subjected to HCD fragmentation. Tandem mass spectra were acquired with FT resolution of 15,000. Normalized collision energy was set to 33 and already targeted precursors were dynamically excluded for further isolation and activation for 45 s with 5 ppm mass tolerance.

Supplemental References

- 1. Pilling AD, Horiuchi D, Lively CM, et al. Kinesin-1 and Dynein are the primary motors for fast transport of mitochondria in *Drosophila* motor axons. Mol Biol Cell. 2006;17:2057-2068.
- 2. Barrio L, Dekanty A, Milán M. MicroRNA-mediated regulation of Dp53 in the *Drosophila* fat body contributes to metabolic adaptation to nutrient deprivation. Cell Rep. 2014;8:528-541.

Table S1. Summary of lifespan experiments.

Table S2. Proteins found to be differentially expressed after inducible *Prosβ5* RNAi (*vs*. *mCherry* RNAi) in larval tissues (nano-LC-ESI-MS/MS proteomics analysis).

Table S3. Proteins found to be differentially expressed after inducible *Prosβ5* RNAi (*vs*. *mCherry* RNAi) in isolated mitochondria from larval tissues (nano-LC-ESI-MS/MS proteomics analysis).

Table S4. Proteins found to be increasingly ubiquitinated* in larvae mitochondria after inducible *Prosβ5* RNAi (*vs*. *mCherry* RNAi) (nano-LC-ESI-MS/MS proteomics analysis).

* Label free quantification following Ub-IP in purified mitochondrial preparations to identify over-ubiquitinated targets